@Article{biocell.2021.014633,
AUTHOR = {BENJIANG QIAN, YOUFENG HUANG, ZHENQIANG QIU, XIAOYAN YING, GUANG YANG, HUIZHANG LI, JIANMING TAN},
TITLE = {Tet methylcytosine dioxygenase 2 suppresses renal cell cancer proliferation and metastasis by regulating the miR-200c-SCD axis},
JOURNAL = {BIOCELL},
VOLUME = {45},
YEAR = {2021},
NUMBER = {3},
PAGES = {599--615},
URL = {http://www.techscience.com/biocell/v45n3/41690},
ISSN = {1667-5746},
ABSTRACT = {Tet methylcytosine dioxygenase 2 (TET2) acts as an antioncogene that is investigated in different cancers. But
the effects of TET2 in renal cell cancer (RCC) is still known little. Here, quantitative real-time PCR (qRT-PCR), Western
blot, and immunofluorescence were performed to exam gene and protein expression. Cell proliferation was measured
using Cell Counting Kit-8 (CCK-8). Transwell assay was performed to detect cell metastasis viability. Flow cytometry
was performed to analyze the cell cycle and cell apoptosis. The effects of TET2 on RCC growth in vivo was analyzed
using a mouse xenograft model.We found that TET2 and miR-200c were decreased in RCC tissues, and
hypermethylation of miR-200c promoter was found. Overexpression of TET2 promoted miR-200c expression by
reducing miR-200c promoter methylation. Additionally, overexpression of TET2 or miR-200c suppressed cell growth
and metastasis. Also, knockdown of miR-200c could moderate TET2 mediated cell growth inhibition. Furthermore,
we found miR-200c directly regulates Stearoyl-CoA desaturase (SCD) gene expression. Moreover, <i>in vivo</i> experiment
results confirmed that TET2 inhibited tumor growth. In conclusion, TET2 acts as an antioncogene in RCC by
regulating the miR-200c-SCD axis and providing a potential target for RCC diagnosis and treatment.},
DOI = {10.32604/biocell.2021.014633}
}